JACC: Basic to Translational Science (Jan 2020)

Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier

  • Patrick H. Kee, MD, PhD,
  • Melanie R. Moody, BSc,
  • Shao-Ling Huang, PhD,
  • Hyunggun Kim, PhD,
  • Xing Yin, MD, PhD,
  • Tao Peng, MD,
  • Susan T. Laing, MD,
  • Melvin E. Klegerman, PhD,
  • Mohammad H. Rahbar, PhD,
  • Deborah Vela, MD,
  • Curtis Genstler, MD, PhD,
  • Kevin J. Haworth, PhD,
  • Christy K. Holland, PhD,
  • David D. McPherson, MD

Journal volume & issue
Vol. 5, no. 1
pp. 1 – 11

Abstract

Read online

Summary: Late in-stent restenosis remains a significant problem. Bare-metal stents were implanted into peripheral arteries in miniature swine, followed by direct intra-arterial infusion of nitric oxide–loaded echogenic liposomes (ELIPs) and anti–intercellular adhesion molecule-1 conjugated ELIPs loaded with pioglitazone exposed to an endovascular catheter with an ultrasonic core. Ultrasound-facilitated delivery of ELIP formulations into stented peripheral arteries attenuated neointimal growth. Local atheroma-targeted, ultrasound-triggered delivery of nitric oxide and pioglitazone, an anti-inflammatory peroxisome proliferator–activated receptor-γ agonist, into stented arteries has the potential to stabilize stent-induced neointimal growth and obviate the need for long-term antiplatelet therapy. Key Words: atherosclerosis, in-stent restenosis, nitric oxide, pioglitazone, ultrasound contrast agent